DR RICHARD WELLER,
WORLD RENOWNED DERMATOLIGIST & RELAXSOL Chief Medical Officer
Richard graduated in medicine at St Thomas’ Hospital, University of London (now part of King’s College, London) and undertook general/internal medicine training in the north of England and in Australia.
Having gained an MRCP he trained in dermatology at the Institute of Dermatology (St John’s) in London, and in Aberdeen and Edinburgh. He spent some time out of his clinical training to complete a research MD degree. Having completed his dermatology training, he gained a scholarship from the University of Edinburgh, and spent three years in post-doctoral research training in the laboratories of Professor Victoria Kolb-Bachofen, Heinrich-Heine Universität, Dusseldorf, and of Dr Tim Billiar, University of Pittsburgh, USA.
He was recruited from America to the post of Senior Lecturer, and latterly Reader in Dermatology and Associate Principal Investigator at the Centre for Inflammation Research, University of Edinburgh.
His time is divided between clinical duties, where he is an honorary NHS Consultant Dermatologist with a particular interest in medical dermatology and eczema, and the University where he has an active research group, and also a significant teaching commitment as Programme Director of the M.Med.Sci degree.
He co-founded a spin-out company, Relaxsol, which developed Dr Weller’s Sunwell Sunscreen based upon his research.
Dr Graham Bell,
Dr Graham Bell has been working in Biotechnology companies for over 20 years. He is currently the Chief Executive Officer at Carbon Life Group Ltd who will be making the initial investment in the spinout.
He also runs his own consultancy company Two Bells Consulting Ltd, which provides interim management, strategic and operational advice to biotechnology companies.
He is retained as a monitoring officer by InnovateUK where he currently monitors 18 Biomedical catalyst grants ranging from therapeutics, clinical devices and diagnostic programmes.
He was previously in charge of corporate development at Cyclacel ltd, overseeing the development of a Cambridge UK based genomics division and running the merger process which took Cyclacel onto the NASDAQ through a reverse merger.
He was a founder and director of NeuroBio Ltd which carries out research and development of therapeutic agents for Alzheimers disease.
Dr Mike FinneN,
Chief Executive Officer
Dr Mike Finnen has wide-ranging senior management experience in the pharmaceutical industry at both large international pharma and start-up companies, working in both discovery and developmental areas.
He has extensive project management experience in both laboratory and clinical project development and has a successful track record in company formation based around new IP.
Prior to founding Relaxsol Mike was Head of Operations for the Edinburgh BioQuarter Commercialisation programme at the College of Medicine and Veterinary Medicine at the University of Edinburgh.
DR Yiyuan Chen,
Dr Yiyuan Chen earned his first degree in Biology from Sichuan University, China and subsequently obtained a PhD in structural biology (drug discovery) at the University of Edinburgh.
He founded the Carbon Holding Group in 2013. Carbon specialises in investment and technology transfer between UK and China majorly in the life science sector, including drug discovery and medical device development.